论文部分内容阅读
目的探讨康柏西普联合玻璃体切除术治疗进展型糖尿病性视网膜病变(proliferative diabetic retinopathy,PDR)的临床效果。方法选择2015年7月—2016年8月收治的90例PDR患者作为研究对象,随机分为观察组与对照组各45例(45眼),观察组采用康柏西普联合玻璃体切除术治疗,对照组仅采用玻璃体切除术治疗,比较两组治疗效果与血管内皮生长因子(vascular endothelial growth factor,VEGF)水平,计数资料组间比较采用χ~2检验,计量资料组间比较采用t检验;以P<0.05为差异有统计学意义。结果观察组总有效率为95.56%,高于对照组的75.56%,差异有统计学意义(χ~2=5.285,P<0.05);治疗后两组VEGF水平均持续降低,且观察组治疗后1个月、2个月水平均低于对照组,差异有统计学意义(P<0.05)。结论康柏西普联合玻璃体切除术治疗PDR可明显提高治疗效果,改善患者VEGF水平,利于预后,值得临床广泛应用。
Objective To investigate the clinical effect of Compaqeep combined with vitrectomy in the treatment of advanced diabetic retinopathy (PDR). Methods Ninety patients (90 eyes) with PDR admitted from July 2015 to August 2016 were randomly divided into observation group (45 cases) and control group (45 eyes). The observation group was treated with Compaqeep combined with vitrectomy, The control group was treated by vitrectomy only. The therapeutic effect and the level of vascular endothelial growth factor (VEGF) were compared between the two groups. Chi-square test was used to compare the two data sets. The t-test was used to compare the measurement data. P <0.05 for the difference was statistically significant. Results The total effective rate in the observation group was 95.56%, which was higher than that in the control group (75.56%), the difference was statistically significant (χ ~ 2 = 5.285, P <0.05) One month and two months lower than the control group, the difference was statistically significant (P <0.05). Conclusions Concomitant vitrectomy for the treatment of PDR can significantly improve the therapeutic effect, improve the level of VEGF in patients with prognosis, it is widely used in clinical.